By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Patients who continued Ozempic through total joint arthroplasty had higher risk for complications compared with those who stopped GLP-1RAs before surgery.

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...

RuPaul's Drag Race star Peppermint was unrecognizable after debuting a 100-pound weight loss transformation—and she did it ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a positive outlook on MDGL stock.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

The GLP-1 (Glucagon-Like Peptide-1) market in the United States is experiencing significant growth, driven by the rising prevalence of type 2 diabetes and obesity. As of February 2025, the market ...